Munich, 20-6-2013 — /europawire.eu/ — EPO President Benoît Battistelli and the Director-General of the Moroccan Industrial and Commercial Property Office (OMPIC), Adil Elmaliki, signed a set of co-operation agreements yesterday in Munich to strengthen the patent system in both Morocco and Europe. The agreements concern, in particular, renewed access to the EPOQUE Net search system for OMPIC examiners, plus various training programmes and exchanges of expertise between the two offices.
President Battistelli paid tribute to “the vision that OMPIC has developed for the Moroccan patent system and is implementing with rigour and consistency.” Director-General Elmaliki in turn stressed “the importance for Morocco of working bilaterally with the EPO; this co‑operation is reciprocal and benefits the strategies of both partners.”
The EPO and OMPIC have been co-operating for ten years now, entering into a strategic partnership with the signature, at the end of 2010, of the first agreement on the validation of European patents. This agreement, now being ratified by Morocco, aims at making the country more attractive for investors while at the same time raising its capacity to support innovation. Its implementation will go hand in hand with capacity-building at OMPIC, in both the examination of Moroccan filings and in the dissemination of technological information in the country.
The validation agreement will enable users of the European patent system to validate their applications and EPO-granted patents in Morocco in addition to 40 European countries. European applications and patents validated for Morocco will have the same legal effects there as Moroccan ones and will be subject to Moroccan law.
Press contact
Oswald Schröder
Spokesperson
European Patent Office
Tel: +49 89 2399 1800
Mobile: +49 163 8399 668
Email: oschroeder@epo.org
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…